GLP1R and metabolic dysfunction-associated steatotic liver disease: On these grounds, our systematic review and meta-analysis aimed at examining the published data of placebo-controlled or active-controlled RCTs, which tested the efficacy and safety of GLP-1 RAs to specifically treat NAFLD or NASH in adults with or without pre-existing T2DM.